Lenalidomide has regularly been one of the best-selling drugs worldwide for years - particularly in the oncological field. Its leading market position is primarily due to its widespread use in the treatment of multiple myeloma and other haematological diseases. In view of this widespread use, it is important to reiterate the applicable safety regulations and the requirements for proper prescribing.

The active substances thalidomide, lenalidomide and pomalidomide belong to the immunomodulatory substances (IMiDs). The three active substances do not differ significantly in their modes of action, but in their areas of application, particularly with regard to the authorised diseases and therapy lines.

To the risk information (available in German only)